AU2012264589B2 - Polycistronic expression system for bacteria - Google Patents

Polycistronic expression system for bacteria Download PDF

Info

Publication number
AU2012264589B2
AU2012264589B2 AU2012264589A AU2012264589A AU2012264589B2 AU 2012264589 B2 AU2012264589 B2 AU 2012264589B2 AU 2012264589 A AU2012264589 A AU 2012264589A AU 2012264589 A AU2012264589 A AU 2012264589A AU 2012264589 B2 AU2012264589 B2 AU 2012264589B2
Authority
AU
Australia
Prior art keywords
gram
gene
positive bacterium
endogenous
promoter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2012264589A
Other languages
English (en)
Other versions
AU2012264589A1 (en
Inventor
Lothar Steidler
Karolien Van Huynegem
Klaas Vandenbroucke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intrexon Actobiotics NV
Original Assignee
Intrexon Actobiotics NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intrexon Actobiotics NV filed Critical Intrexon Actobiotics NV
Publication of AU2012264589A1 publication Critical patent/AU2012264589A1/en
Assigned to INTREXON ACTOBIOTICS NV reassignment INTREXON ACTOBIOTICS NV Alteration of Name(s) of Applicant(s) under S113 Assignors: ACTOGENIX N.V.
Application granted granted Critical
Publication of AU2012264589B2 publication Critical patent/AU2012264589B2/en
Priority to AU2017203281A priority Critical patent/AU2017203281B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/746Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
AU2012264589A 2011-06-01 2012-06-01 Polycistronic expression system for bacteria Ceased AU2012264589B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2017203281A AU2017203281B2 (en) 2011-06-01 2017-05-16 Polycistronic expression system for bacteria

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP11168495 2011-06-01
EP11168495.7 2011-06-01
EP11173588.2 2011-07-12
EP11173588 2011-07-12
PCT/EP2012/060431 WO2012164083A1 (en) 2011-06-01 2012-06-01 Polycistronic expression system for bacteria

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2017203281A Division AU2017203281B2 (en) 2011-06-01 2017-05-16 Polycistronic expression system for bacteria

Publications (2)

Publication Number Publication Date
AU2012264589A1 AU2012264589A1 (en) 2014-01-09
AU2012264589B2 true AU2012264589B2 (en) 2017-02-16

Family

ID=46354175

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2012264589A Ceased AU2012264589B2 (en) 2011-06-01 2012-06-01 Polycistronic expression system for bacteria
AU2017203281A Ceased AU2017203281B2 (en) 2011-06-01 2017-05-16 Polycistronic expression system for bacteria

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2017203281A Ceased AU2017203281B2 (en) 2011-06-01 2017-05-16 Polycistronic expression system for bacteria

Country Status (13)

Country Link
US (3) US9920324B2 (cg-RX-API-DMAC7.html)
EP (2) EP3360967B1 (cg-RX-API-DMAC7.html)
JP (3) JP6175428B2 (cg-RX-API-DMAC7.html)
KR (1) KR102066292B1 (cg-RX-API-DMAC7.html)
CN (2) CN103562390B (cg-RX-API-DMAC7.html)
AU (2) AU2012264589B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013030824A8 (cg-RX-API-DMAC7.html)
CA (2) CA3136084A1 (cg-RX-API-DMAC7.html)
DK (1) DK2714912T3 (cg-RX-API-DMAC7.html)
ES (1) ES2676877T3 (cg-RX-API-DMAC7.html)
HU (1) HUE039577T2 (cg-RX-API-DMAC7.html)
RU (2) RU2766157C2 (cg-RX-API-DMAC7.html)
WO (1) WO2012164083A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2714912T3 (en) 2011-06-01 2018-08-13 Intrexon Actobiotics Nv POLYCISTRONIC EXPRESSION SYSTEM FOR BACTERIA
US9593339B1 (en) * 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
EP3034610A1 (en) * 2013-08-13 2016-06-22 The Kitasato Institute Novel terpenoid compound and method for producing same
CA2969100C (en) * 2014-12-03 2023-03-21 Anaeropharma Science, Inc. Coexpression plasmid
CN107208107B (zh) 2014-12-23 2021-07-09 伊利亚制药公司 伤口愈合的方法
EP3295173B1 (en) * 2015-05-10 2025-11-05 Ventana Medical Systems, Inc. Compositions and methods for simultaneous inactivation of alkaline phosphatase and peroxidase enzymes during automated multiplex tissue staining assays
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
EP3919065B9 (en) 2016-01-14 2024-01-24 Intrexon Actobiotics NV Compositions and methods for the treatment of type 1 diabetes
CN118813511A (zh) * 2016-09-02 2024-10-22 英特瑞克斯顿阿克图比奥帝克斯有限公司 稳定表达il-10和胰岛素的遗传修饰的细菌
KR102469701B1 (ko) 2016-09-13 2022-11-22 인트랙슨 액토바이오틱스 엔.브이. 점막부착성 미생물
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
GB201906775D0 (en) * 2019-05-14 2019-06-26 Res & Innovation Uk Synthetic genome
AU2020356592A1 (en) 2019-09-27 2022-04-07 Intrexon Actobiotics Nv D/B/A Precigen Actobio Treatment of celiac disease
WO2024003873A1 (en) 2022-06-30 2024-01-04 Intrexon Actobiotics Nv D/B/A Precigen Actobio Single variable domain antibodies against tumor necrosis factor-alpha

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001062944A2 (en) * 2000-02-24 2001-08-30 Siga Pharmaceuticals, Inc. Intergenic and intragenic integration sites for foreign gene expression in recombinant s. gordonii strains

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB227835A (en) 1924-01-15 1925-04-09 Harry Odell Improvements in feeding mechanism for embossing and other printing presses
JPS58116498A (ja) 1981-12-28 1983-07-11 Takeda Chem Ind Ltd Il‐2をコードする新規伝令rnaの製造法
DE3377363D1 (en) 1982-03-31 1988-08-18 Ajinomoto Kk Gene coding for interleukin-2 polypeptide, recombinant dna carrying said gene, cell lines possessing the recombinant dna,and method for producing interleukin-2 using said cells
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4752585A (en) 1985-12-17 1988-06-21 Cetus Corporation Oxidation-resistant muteins
JPH01196296A (ja) * 1988-01-29 1989-08-08 Toray Ind Inc 動物細胞用発現ベクター
US4919918A (en) 1988-03-14 1990-04-24 Spectrum Consumer Products Co., Inc. Non-alcoholic mouthwash
US5972685A (en) 1988-07-21 1999-10-26 Iowa State University Research Foundation, Inc. Oral administration of coprostanol producing microorganisms to humans to decrease plasma cholesterol concentration
GB9006400D0 (en) 1990-03-22 1990-05-23 Ciba Geigy Ag Bacterial vectors
CA2104104A1 (en) 1991-02-14 1992-09-03 Daniel K. Podolsky Intestinal trefoil proteins
US6221840B1 (en) 1991-02-14 2001-04-24 The General Hospital Corporation Intestinal trefoil proteins
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
GB9126306D0 (en) 1991-12-11 1992-02-12 Unilever Plc Mouthwash compositions
WO1993017117A1 (en) 1992-02-27 1993-09-02 Lynxvale Limited Heterologous gene expression in lactococcus, and the expression products therefrom
US5223285A (en) 1992-03-31 1993-06-29 Abbott Laboratories Nutritional product for pulmonary patients
EP0569604A1 (en) 1992-04-07 1993-11-18 Societe Des Produits Nestle S.A. Integrative gene-expression in Streptococcus salivarius ssp.thermophilus
US5229109A (en) 1992-04-14 1993-07-20 Board Of Regents, The University Of Texas System Low toxicity interleukin-2 analogues for use in immunotherapy
US5700782A (en) 1993-05-28 1997-12-23 Abbott Laboratories Enteral nutritional product
WO1996032486A1 (en) 1995-04-11 1996-10-17 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Method for the construction of vectors for lactic acid bacteria like lactobacillus such that the bacteria can efficiently express, secrete and display proteins at the surface
US5695746A (en) 1995-07-28 1997-12-09 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Liquid dentifrice with mouthwash fresh taste
GB9521568D0 (en) 1995-10-20 1995-12-20 Lynxvale Ltd Delivery of biologically active polypeptides
WO1997026855A1 (en) 1996-01-24 1997-07-31 Warner-Lambert Company Peroxide/essential oils containing mouthwash compositions and two-part mouthwash systems
GB9611364D0 (en) 1996-05-31 1996-08-07 Smithkline Beecham Plc Composition
US5993785A (en) 1996-09-18 1999-11-30 Erling Johansen Mouthwash compositions
US5869118A (en) 1996-11-13 1999-02-09 Abbott Laboratories Gellan gum to improve physical stability of liquid nutritional products
US6171611B1 (en) 1997-11-12 2001-01-09 Dante J. Picciano Iodine-containing nasal moisturizing saline and mouthwash solutions
US5897872A (en) 1997-11-12 1999-04-27 Picciano; Dante J. Iodine-containing nasal moisturizing saline solution
ES2234306T3 (es) 1998-09-28 2005-06-16 Warner-Lambert Company Llc Administracion enterica y via colon usando capsulas de hpmc.
WO2000022909A2 (en) 1998-10-19 2000-04-27 Biotech Australia Pty. Limited Systems for oral delivery
EP1123314B1 (en) 1998-10-20 2004-02-18 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Use of a cytokine-producing lactococcus strain to treat colitis
US6929931B1 (en) 1999-06-30 2005-08-16 Nestec S.A. Expression contructs using Lactobacillus delbrueckii subsp. lactis lac repressor protein and its lac repressor binding site, microorganisms and methods thereof
PT1739178E (pt) 1999-07-05 2010-11-17 Actogenix Nv Libertação de péptidos trifólios
US7029842B2 (en) * 2000-04-07 2006-04-18 Novozymes A/S Signal sequence trapping
GB0013810D0 (en) 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
ES2266515T3 (es) 2001-05-03 2007-03-01 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Cepa de lactococcus con autocontencion.
EP1319410A1 (en) * 2001-12-11 2003-06-18 Société des Produits Nestlé S.A. Use of micro-organisms for a directed delivery of substances to specific parts of the gut
MXPA05001520A (es) 2002-07-08 2005-05-05 Joe S Wilkins Jr Formulaciones antibacteriales.
WO2004046346A2 (en) 2002-11-15 2004-06-03 Vib Vzw Self-containing lactobacillus strain
MXPA05008131A (es) 2003-01-31 2005-10-05 Univ Pennsylvania Metodos para la modulacion de una respuesta inflamatoria.
EP1493816A1 (en) * 2003-07-02 2005-01-05 Friesland Brands B.V. Methods and means for regulating gene expression
US7569215B2 (en) 2003-07-18 2009-08-04 Massachusetts Institute Of Technology Mutant interleukin-2 (IL-2) polypeptides
WO2005071088A2 (en) * 2003-12-24 2005-08-04 Cerus Corporation Recombinant nucleic acid molecules encoding fusion proteins comprising antigens and bacterial secretory signal polypeptides, expression cassettes, and bacteria, and methods of use thereof
US7842289B2 (en) * 2003-12-24 2010-11-30 Aduro Biotech Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof
JP2007527242A (ja) 2004-03-05 2007-09-27 カイロン コーポレーション 治療剤の患者耐容性を予測するためのインビトロ試験システム
US7495092B2 (en) * 2005-01-14 2009-02-24 North Carolina State University Compositions comprising promoter sequences and methods of use
US7764366B2 (en) 2006-07-11 2010-07-27 Besi North America, Inc. Robotic die sorter with optical inspection system
JP2009544679A (ja) * 2006-07-25 2009-12-17 ザ ユニヴァーシティー コート オブ ザ ユニヴァーシティー オブ ダンディー 異常な細胞増殖に関連する疾患の治療におけるレチノイド及び小分子のNrf2アンタゴニストとしての使用
KR101557509B1 (ko) * 2007-01-12 2015-10-06 액토제닉스 엔.브이. 락토코커스 프로모터 및 그것의 용도
KR101821417B1 (ko) 2009-04-30 2018-01-23 인트랙슨 액토바이오틱스 엔.브이. 유산균의 냉동건조에 사용하기 위한 냉동보호제
PE20181077A1 (es) 2011-02-10 2018-07-05 Roche Glycart Ag Polipeptidos interleuquina-2-mutantes
US9669071B2 (en) 2011-03-11 2017-06-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for stimulating T lymphocytes with IL-2
DK2714912T3 (en) 2011-06-01 2018-08-13 Intrexon Actobiotics Nv POLYCISTRONIC EXPRESSION SYSTEM FOR BACTERIA
JP2014526472A (ja) 2011-09-08 2014-10-06 ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド 免疫応答を調節するための材料および方法
EP3919065B9 (en) 2016-01-14 2024-01-24 Intrexon Actobiotics NV Compositions and methods for the treatment of type 1 diabetes

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001062944A2 (en) * 2000-02-24 2001-08-30 Siga Pharmaceuticals, Inc. Intergenic and intragenic integration sites for foreign gene expression in recombinant s. gordonii strains

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BRUCKNER, R. FEMS Microbiology Letters, 1997, Vol. 151, pages 1-8 *
DOBINSKY, S. et al., Plasmid, 2002, Vol. 47, pages 10-17 *

Also Published As

Publication number Publication date
RU2013157300A (ru) 2015-07-20
HK1257050A1 (en) 2019-10-11
RU2018102374A (ru) 2019-02-21
KR102066292B1 (ko) 2020-01-14
EP2714912B1 (en) 2018-05-02
EP3360967A1 (en) 2018-08-15
AU2017203281A1 (en) 2017-06-08
CN107267546A (zh) 2017-10-20
EP3360967B1 (en) 2020-09-09
RU2644346C2 (ru) 2018-02-08
RU2766157C2 (ru) 2022-02-08
US20140105863A1 (en) 2014-04-17
JP6867866B2 (ja) 2021-05-12
US10988770B2 (en) 2021-04-27
US9920324B2 (en) 2018-03-20
HK1244033A1 (zh) 2018-07-27
CN107267546B (zh) 2021-08-17
WO2012164083A1 (en) 2012-12-06
DK2714912T3 (en) 2018-08-13
HUE039577T2 (hu) 2019-01-28
CA3136084A1 (en) 2012-12-06
ES2676877T3 (es) 2018-07-25
JP2021097671A (ja) 2021-07-01
BR112013030824A8 (pt) 2018-04-03
BR112013030824A2 (pt) 2016-12-06
CA2837634A1 (en) 2012-12-06
US20210163961A1 (en) 2021-06-03
KR20140027405A (ko) 2014-03-06
CN103562390A (zh) 2014-02-05
AU2017203281B2 (en) 2019-01-03
CN103562390B (zh) 2017-07-18
US20180187203A1 (en) 2018-07-05
CA2837634C (en) 2021-12-14
RU2018102374A3 (cg-RX-API-DMAC7.html) 2021-03-30
JP6175428B2 (ja) 2017-08-02
JP2014518062A (ja) 2014-07-28
AU2012264589A1 (en) 2014-01-09
EP2714912A1 (en) 2014-04-09
JP2017200477A (ja) 2017-11-09

Similar Documents

Publication Publication Date Title
US10988770B2 (en) Polycistronic expression system for bacteria
JP5584470B2 (ja) ラクトコッカスプロモーター及びその使用
CA2738781C (en) Reduced colonization of microbes at the mucosa
CA2787787A1 (en) Transformation plasmid
US11549115B2 (en) Compositions and methods for regulated gene expression
HK1257050B (en) Polycistronic expression system for bacteria
HK1244033B (zh) 用於细菌的多顺反子表达系统
Chen et al. Genetic operation system of lactic acid bacteria and its applications
US20190359695A1 (en) Recombinant expression systems and products
HK1227928A1 (en) Lactococcus promoters and uses thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired